Peroxisome proliferator-activated receptor γ agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity

Molecular Cancer Therapeutics

Volumn 8, Issue 1, 2009, Pages 94-100

  Ihle, Nathan T ^a   Lemos, Robert ^a   Schwartz, David ^a   Oh, Junghwan ^a   Halter, Robert J ^b   Wipf, Peter ^b   Kirkpatrick, Lynn ^c   Powis, Garth ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c Oncothyreon Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID 4 DIALLYLAMINOMETHYLENE 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 2 OXA CYCLOPENTA[ALPHA]PHENANTHREN 11 YL ESTER); DEOXYGLUCOSE; FLUORODEOXYGLUCOSE F 18; GLUCOSE; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PIOGLITAZONE; PX 866; UNCLASSIFIED DRUG;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL STRAIN A 549; CELL STRAIN HT29; CELL STRAIN L 6; CELL SURVIVAL; COLON CANCER; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG INHIBITION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IMAGE ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MOUSE; MUSCLE CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCID MOUSE; TUMOR XENOGRAFT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DISEASE PROGRESSION; GLUCOSE; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; GLUCOSE-6-PHOSPHATE; GONANES; HUMANS; HYPERGLYCEMIA; MICE; NEOPLASMS; PPAR GAMMA; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 58149505585     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0714     Document Type: Article

References (35)

1. Cantley LC. The phosphoinositide 3-kinase pathway. Science (NY) 2002;296:1655-7.
2. Ihle NT, Paine-Murrieta G, Berggren MI, et al. The phosphatidylinositol- 3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol Cancer Ther 2005;4:1349-57.
3. 473 phosphorylation: a basis for decreased insulin-stimulated glucose transport. Clin Cancer Res 2004;10:7192-8.
4. Knight ZA, Gonzalez B, Feldman ME, et al. A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell 2006;125:733-47.
5. Graupera M, Guillermet-Guibert J, Foukas LC, et al. Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration. Nature 2008;453:662-6.
6. Foukas LC, Claret M, Pearce W, et al. Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 2006;441:366-70.
7. Luo J, Sobkiw CL, Hirshman MF, et al. Loss of class IA PI3K signaling in muscle leads to impaired muscle growth, insulin response, and hyperlipidemia. Cell Metab 2006;3:355-66.
8. Garofalo RS, Orena SJ, Rafidi K, et al. Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKBβ. J Clin Invest 2003;112:197-208.
9. George S, Rochford JJ, Wolfrum C, et al. A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science (NY) 2004;304:1325-8.
10. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002;14:381-95.
11. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
12. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 1998;95:15587-91.
13. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005;4:988-1004.
14. Marone R, Cmiljanovic V, Giese B, Wymann MP. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta 2008;1784:159-85.
15. Kortmansky SNS, O'Reilly E, Shah M, et al. Management of hyperglycemia in patients with metastatic pancreatic cancer receiving UCN-01 and fluorouracil. J Clin Oncol 2004 ASCO Annu Meet Proc (Post-Meet Ed) 2004;22:2140.
16. Bellmunt J, Szczylik C, Feingold J, Strahs A, Berkenblit A. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 2008;19:1387-92.
17. Musi N, Goodyear LJ. Insulin resistance and improvements in signal transduction. Endocrine 2006;29:73-80.
18. 18fluoro-deoxyglucose positron emission tomography study. Diabetes 2002;51:3384-90.
19. Ihle NT, Williams R, Chow S, et al. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther 2004;3:763-72.
20. Williams R, Baker AF, Ihle NT, Winkler AR, Kirkpatrick L, Powis G. The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling. Cancer Chemother Pharmacol 2006;58:444-50.
21. Chaussade C, Rewcastle GW, Kendall JD, et al. Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. Biochem J 2007;404:449-58.
22. Cheng AY, Fantus IG. Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ 2005;172:213-26.
23. Michalik L, Desvergne B, Wahli W. Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer 2004;4:61-70.
24. Keshamouni VG, Reddy RC, Arenberg DA, et al. Peroxisome proliferator-activated receptor-γ activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 2004;23:100-8.
25. Girnun GD, Naseri E, Vafai SB, et al. Synergy between PPARg ligands and platinum-based drugs in cancer. Cancer Cell 2007;11:395-406.
26. Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EP. Use of the peroxisome proliferator-activated receptor (PPAR) γ ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat 2003;79:391-7.
27. Kulke MH, Demetri GD, Sharpless NE, et al. A phase II study of troglitazone, an activator of the PPARγ receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J 2002;8:395-9.
28. Hashiramoto M, James DE. Snareing GLUT4 at the plasma membrane in muscle and fat. Adv Exp Med Biol 1998;441:47-61.
29. Ishiki M, Klip A. Minireview: recent developments in the regulation of glucose transporter-4 traffic: new signals, locations, and partners. Endocrinology 2005;146:5071-8.
30. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005;202:654-62.
31. Howes AL, Chiang GG, Lang ES, et al. The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures. Mol Cancer Ther 2007;6:2505-14.
32. Jiang BH, Liu LZ. AKTsignaling in regulating angiogenesis. Curr Cancer Drug Targets 2008;8:19-26.
33. Elmendorf JS, Damrau-Abney A, Smith TR, David TS, Turinsky J. Insulin-stimulated phosphatidylinositol 3-kinase activity and 2-deoxy-D-glucose uptake in rat skeletal muscles. Biochem Biophys Res Commun 1995;208:1147-53.
34. Murakami T, Nishiyama T, Shirotani T, et al. Identification of two enhancer elements in the gene encoding the type 1 glucose transporter from the mouse which are responsive to serum, growth factor, and oncogenes. J Biol Chem 1992;267:9300-6.
35. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.